<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124498</url>
  </required_header>
  <id_info>
    <org_study_id>CABIO-CIK-1701</org_study_id>
    <nct_id>NCT03124498</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA</brief_title>
  <official_title>A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of Autologous Cytokine-Induced Killer (CIK) Cell for Patients With Hepatocellular Carcinoma (HCC) After Transarterial Chemoembolization (TACE), Percutaneous Ethanol Injection Therapy (PEIT) or RadioFrequency Ablation (RFA) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuan An Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chuan An Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of Autologous&#xD;
      Cytokine-Induced Killer (CIK) Cell for Patients with Hepatocellular Carcinoma (HCC) after&#xD;
      Transarterial Chemoembolization (TACE), Percutaneous Ethanol Injection Therapy (PEIT) or&#xD;
      RadioFrequency Ablation (RFA) Therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Presence or absence of Dose-Limiting Toxicity</measure>
    <time_frame>5 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Disease Control Rate</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CIK Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I - Three dose levels escalated according to 3+3 rule&#xD;
Phase II - The recommended dose level according to the results from Phase I</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK Cell</intervention_name>
    <description>Autologous cytokine-induced killer (CIK) cell</description>
    <arm_group_label>CIK Cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 to 80 years old men and women;&#xD;
&#xD;
          2. HCC diagnosed with typical imaging findings, or confirmed by needle liver biopsy;&#xD;
&#xD;
          3. Patients who are not a transplant candidate;&#xD;
&#xD;
          4. Patients who have no extrahepatic metastasis and are with measurable residual tumor&#xD;
             after TACE, PEIT or RFA therapy;&#xD;
&#xD;
          5. Patients who have a life expectancy of at least 6 months;&#xD;
&#xD;
          6. Child-Pugh Class should be A or B;&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status score was 0-3;&#xD;
&#xD;
          8. Patients who have clinical laboratory test results as follows:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/µL or White blood cell ≥ 4,000/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 50,000/µL&#xD;
&#xD;
               -  Blood creatinine ≤ 1.5 x upper limit of normal&#xD;
&#xD;
               -  Total bilirubin &lt; 3 x upper limit of normal&#xD;
&#xD;
               -  Albumin ≥ 2.8 g/dL&#xD;
&#xD;
               -  International normalized ratio (INR) / Partial thromboplastin time (PTT) &lt; 1.5 x&#xD;
                  upper limit of normal&#xD;
&#xD;
          9. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have infiltrative or diffuse HCC;&#xD;
&#xD;
          2. Patients who have significant cardiovascular disease such as myocardial infarction&#xD;
             occurred within recent 6 months, chronic heart failure or unstable coronary artery&#xD;
             disease;&#xD;
&#xD;
          3. Patients who plan to receive systemic chemotherapy or target therapy;&#xD;
&#xD;
          4. Patients with other malignant tumor within the past 5 years before treatment;&#xD;
&#xD;
          5. Pregnant or lactating patients;&#xD;
&#xD;
          6. Patients with hemorrhage/bleeding event;&#xD;
&#xD;
          7. Patients with uncontrolled infections;&#xD;
&#xD;
          8. Known or suspected allergy to the investigational agent or any agent given in&#xD;
             association with this trial;&#xD;
&#xD;
          9. Patients who have current Human Immunodeficiency Virus (HIV) or Treponema Pallidum&#xD;
             (TP) infection;&#xD;
&#xD;
         10. Patients who are suffering from serious autoimmune disease;&#xD;
&#xD;
         11. Patients who have had long term use of or are using an immunosuppressant;&#xD;
&#xD;
         12. History of organ transplant;&#xD;
&#xD;
         13. Prior use of any anti-cancer treatments within 30 days or 5 half-lives (whichever is&#xD;
             longer), except TACE, PEIT and RFA therapy;&#xD;
&#xD;
         14. Patients who have participated in another clinical study and received treatment within&#xD;
             30 days prior to the screening visit;&#xD;
&#xD;
         15. Mental conditions rendering the patient incapable of understanding the nature, scope,&#xD;
             and consequences of the study;&#xD;
&#xD;
         16. Other situations that the researchers considered unsuitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keanyee Lai</last_name>
    <phone>+886-02-27928987</phone>
    <email>laikeanyee@gmail.com</email>
  </overall_contact>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma, Autologous Cytokine-Induced Killer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

